The clinical education
Choose the strategy before you choose the drug.
Osteoporosis medicines are not interchangeable, and the “strongest” medicine is not automatically the right one. The starting point is the fracture the woman is at risk of having, the health factors that shape that risk, and a plan for what happens after the first treatment.
“The goal of osteoporosis treatment is not to make a DXA report prettier. It is to prevent fractures.”
A T-score is important. It is not the whole decision.
A T-score compares bone density with the average density of a healthy young adult. A score at or below minus 2.5 at an accepted site meets the bone-density definition of osteoporosis. But a woman can be at important fracture risk with a higher T-score. A hip or vertebral fracture may establish osteoporosis and warrant treatment regardless of the T-score. Some women with osteopenia may also benefit from medication when a prior fragility fracture, clinical risk factors, or an estimated fracture probability raises concern.
In the United States, the Bone Health and Osteoporosis Foundation uses commonly applied treatment thresholds for some people with osteopenia: a 10-year probability of hip fracture of at least 3 percent or major osteoporotic fracture of at least 20 percent by FRAX. Those are guideposts, not a rule that replaces clinical judgment. FRAX does not capture every important detail, including all patterns of falls, how recent or multiple fractures are, rapid bone loss, or every treatment-related risk. A number below a threshold does not automatically mean “no treatment,” and a low T-score alone does not answer every question.
The fuller picture can include prior fractures and how they happened, DXA results at the spine and hip, age, family history, fall risk, medical conditions, medicines such as glucocorticoids, cancer treatment, kidney function, menopause timing, and the rate of bone loss. The Bone Health collection on osteopenia and fracture risk explains why the scan needs that context.
Who may need medication?
Medication is commonly recommended for women with osteoporosis or sufficiently high fracture risk under applicable guidelines. It may also be appropriate for selected women with osteopenia, especially after certain fragility fractures or when a risk assessment shows a high chance of fracture. Guidelines do not define every threshold in exactly the same way. The BHOF guide, Endocrine Society, AACE, and ACP draw on different evidence frameworks and may use different categories or wording for treatment eligibility and “very high” risk. ACP’s living guideline recommends bisphosphonates as initial therapy for many adults with primary osteoporosis and reserves romosozumab or teriparatide followed by a bisphosphonate for women at very high risk. Endocrine Society and AACE guidance also use risk stratification to identify women who may benefit from anabolic-first treatment. Your clinician should explain which framework informs the recommendation and how your own history fits it.
This is not a reason to medicalize every low bone-density result. It is a reason to ask what the result means beside the full history. Some women need medication now; others may be best served by addressing specific risk factors, supporting bone and muscle health, and monitoring at an appropriate interval.
Treatment intensity follows fracture risk
For many women who need treatment, an antiresorptive medicine is an appropriate starting point. Bisphosphonates slow bone breakdown, and denosumab is another antiresorptive option. For women at very high fracture risk, such as some women with multiple or recent fragility fractures or severe osteoporosis, a bone-building (anabolic) medicine first may be considered. The definitions used to identify “very high risk” vary across guidelines. When an anabolic medicine is chosen, an antiresorptive medicine is generally needed afterward to preserve the gains.
“I don’t need to choose the least scary medication on the internet. I need to understand my fracture risk and build a treatment plan around it.”
Myths that can make a decision harder
- “My T-score isn’t minus 2.5, so I can’t need medication.” A T-score is one part of the picture. Fracture history and overall risk can change the recommendation.
- “Calcium is enough.” Calcium and vitamin D support bone health. They do not reliably replace fracture-reducing medicine when a woman’s risk makes medication appropriate.
- “Exercise can replace medication regardless of fracture risk.” Strength, balance, and weight-bearing activity matter, but they do not automatically substitute for indicated treatment.
- “Reclast destroys your jaw.” Osteonecrosis of the jaw is a rare complication at osteoporosis doses. Risk differs by dose, duration, dental health and procedures, and other factors; oncology dosing is a different context. The rare risk deserves proportionate counseling, not a reason to ignore a more common fracture risk.
- “Once you start Prolia, you can never stop.” Denosumab can be stopped when there is a clinician-directed follow-on plan. It should not be treated like a bisphosphonate holiday or stopped without an exit plan.
- “All osteoporosis medications cause fractures.” Medicines have benefits and possible harms. These treatments are prescribed to lower fracture risk. The balance depends on the particular drug and the woman’s clinical situation.
- “Bone-building medicine is only for people who failed everything else.” For some women at very high risk, an anabolic-first sequence is an evidence-based option to discuss.
- “Every osteoporosis drug needs a drug holiday.” A drug holiday is a bisphosphonate concept. It is not a universal osteoporosis-medication concept.
- “If my DXA didn’t improve, the medicine didn’t work.” A stable result can be meaningful when treatment is reducing bone loss and lowering fracture risk. The trend, measurement precision, adherence, and clinical picture matter.
- “If I had side effects from one medicine, I can’t treat my osteoporosis.” Intolerance to one treatment does not close every option. A different medicine, route, or sequence may fit better.
For a broader conversation about treatment-related bone loss, see Cancer Treatment & Bone Health. Bone risk can also intersect with muscle, nutrition, and activity; our Body Composition collection explores those midlife changes, and the Sleep collection addresses a common barrier to recovery and movement. Musculoskeletal pain deserves its own assessment rather than being automatically attributed to osteoporosis or menopause.